News & Updates
Filter by Specialty:
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
25 Jul 2023
Ηeparan sulphate elevated in acute exacerbations of COPD
Circulating levels of heparan sulphate (HS) are higher in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), a study has found. This increase appears to be associated with the aetiology of AECOPD.
Ηeparan sulphate elevated in acute exacerbations of COPD
25 Jul 2023
Study: Older COVID-19 patients with epilepsy, multimorbidity highly vulnerable
Factors such as older age (>65 years), ventilator use, and higher comorbidity all contribute to increased mortality risk with COVID-19 among patients with epilepsy, as reported in a study.
Study: Older COVID-19 patients with epilepsy, multimorbidity highly vulnerable
24 Jul 2023
Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis
A 3-month course of prolonged-release pirfenidone formulation appears to be safe and efficacious in the treatment of patients with postacute sequelae of COVID-19 (PASC)-pulmonary fibrosis, as shown in a study.
Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis
22 Jul 2023
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
15 Jul 2023
TCM shows potential for mild COVID-19 caused by Omicron
Longyizhengqi (LYZQ) granule, a traditional Chinese medicine (TCM), might be a promising drug for the treatment of mild COVID-19 caused by the Omicron variant, a prospective study from China suggests.